Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-31
2006-10-31
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S330000, C530S331000
Reexamination Certificate
active
07129215
ABSTRACT:
Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.
REFERENCES:
patent: 5556942 (1996-09-01), Kauvar et al.
patent: 5599903 (1997-02-01), Kauvar et al.
patent: 5763570 (1998-06-01), Kauvar et al.
patent: 5767086 (1998-06-01), Kauvar et al.
patent: 5786336 (1998-07-01), Kauvar et al.
patent: 5955432 (1999-09-01), Kauvar et al.
patent: 6627732 (2003-09-01), Sakon et al.
patent: 7029695 (2006-04-01), Redelmeier et al.
patent: 2003/0100511 (2003-05-01), Kauvar et al.
patent: 0645397 (1998-09-01), None
patent: WO95/08563 (1995-03-01), None
patent: WO 95/09865 (1995-04-01), None
patent: WO 95/09866 (1995-04-01), None
patent: WO96/40205 (1996-12-01), None
patent: WO 98/09986 (1998-03-01), None
patent: WO99/54346 (1999-10-01), None
patent: WO00/44366 (2000-08-01), None
Hamilton & Batist “TLK-199” IDrugs, 2005, 8(8), 662-669.
U.S. Appl. No. 11/326,975, filed Jan. 5, 1996, Steven R. Schow.
Ciaccio et al., “Modulation of detoxification gene expression in human colon HT29 cells by glutathione S-transferase inhibitors”, Mol. Pharmacol., 48(4), 639-647 (1995).
Johansson et al., “The human glutathione transferase P1-1 specific inhibitor TER117 designed for overcoming cytostatic-drug resistance is also a strong inhibitor of glyoxalase l”, Mol. Pharmacol., 57, 69-624 (2000).
Lyttle et al., “Isozyme-specific glutathione S-transferase inhibitors: design and synthesis”, J. Med. Chem., 37(1), 189-194 (1994).
Lyttle et al., “Glutathione S-transferase activates novel alkylating agents”, J. Med. Chem., 37(10), 1501-1507 (1994).
Shiotsuki et al., “Inhibition of glutathione transferase by S-benzyl glutathione analogous to the conjugate of saligenin cyclic phosphate”, Pestic. Biochem. Physiol., 37(2), 121-129 (1990).
Townsend et al., Efficacy of a Glutathione S-Transferase π-activated Prodrug in Platinum-resistant Ovarian Cancer Cells:Molecular Cancer Therapeutics. (Oct. 2002) 1:1089-1095.
Vince et al., “Studies on the inhibition of glyoxalase l by S-substituted glutathiones”, J. Med. Chem., 14(5), 402-404 (1971).
Aurrecoechea Natalia
Kelson Andrew B.
Macsata Robert W.
Robinson Louise
Sanchez Anthony J.
Telik, Inc.
Tsang Cecilia J.
LandOfFree
Tripeptide and tetrapeptide thioethers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tripeptide and tetrapeptide thioethers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tripeptide and tetrapeptide thioethers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3662482